Pharmaceutical and life sciences companies have won admirers for innovating quickly in a very tough situation this year. With unprecedented pressure on regulators and pharmaceutical organisations to bring COVID-19 treatments to market as soon as possible, we should expect quality functions within pharma companies to come under a brighter spotlight.

Based on our experience transforming quality functions with leading pharmaceutical companies, we see enormous potential for quality to act as a value creator across an organisation’s operations. Here we assess the characteristics of high‑performance quality functions and highlight areas of particular interest for the months and years ahead.

Click here to read the article.